Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Fifth Fl Waterloo Exchange, Waterloo Road DUBLIN 4 |
Tel: | 1-650-4962717 |
Website: | https://www.jazzpharma.com |
IR: | See website |
Key People | ||
Bruce C. Cozadd Chairman of the Board, Chief Executive Officer | Renee D. Gala President, Chief Operating Officer | Philip Johnson Chief Financial Officer, Executive Vice President |
Robert Iannone Executive Vice President, Global Head of Research and Development | Neena M. Patil Executive Vice President, Chief Legal Officer | Patricia Carr Senior Vice President, Chief Accounting Officer |
Finbar Larkin Senior Vice President - Technical Operations | Samantha Pearce Senior Vice President, Europe and International |
Business Overview |
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD). |
Financial Overview |
For the fiscal year ended 31 December 2023, Jazz Pharmaceuticals PLC revenues increased 5% to $3.83B. Net income totaled $414.8M vs. loss of $224.1M. Revenues reflect Xyrem segment increase of 37% to $2.71B, Rylaze segment increase of 40% to $394.2M, United States segment increase of 4% to $3.49B, Europe segment increase of 12% to $269.2M. Net Income reflects Acquired in-process research and develop decrease of 96% to $19M (expense). |
Employees: | 2,800 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10,930M as of Dec 31, 2023 |
Annual revenue (TTM): | $3,834M as of Dec 31, 2023 |
EBITDA (TTM): | $1,217M as of Dec 31, 2023 |
Net annual income (TTM): | $414.83M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,049M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $4,092M as of Dec 31, 2023 |
Shares outstanding: | 62,345,283 as of Feb 21, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |